NO932437D0 - Fusjonsproteiner med blandet spesifitet - Google Patents

Fusjonsproteiner med blandet spesifitet

Info

Publication number
NO932437D0
NO932437D0 NO932437A NO932437A NO932437D0 NO 932437 D0 NO932437 D0 NO 932437D0 NO 932437 A NO932437 A NO 932437A NO 932437 A NO932437 A NO 932437A NO 932437 D0 NO932437 D0 NO 932437D0
Authority
NO
Norway
Prior art keywords
fusion proteins
patient
cellular adhesion
administered
inhibit
Prior art date
Application number
NO932437A
Other languages
English (en)
Other versions
NO313241B1 (no
NO932437L (no
Inventor
Alejandro A Aruffo
Peter S Linsley
Jeffery A Ledbetter
Nitin K Damle
Jr Perry H Fell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO932437D0 publication Critical patent/NO932437D0/no
Publication of NO932437L publication Critical patent/NO932437L/no
Publication of NO313241B1 publication Critical patent/NO313241B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19932437A 1991-01-24 1993-07-05 Fusjonsproteiner med blandet spesifisitet NO313241B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/645,522 US5709859A (en) 1991-01-24 1991-01-24 Mixed specificity fusion proteins
PCT/US1992/000616 WO1992012994A1 (en) 1991-01-24 1992-01-24 Mixed specificity fusion proteins

Publications (3)

Publication Number Publication Date
NO932437D0 true NO932437D0 (no) 1993-07-05
NO932437L NO932437L (no) 1993-09-17
NO313241B1 NO313241B1 (no) 2002-09-02

Family

ID=24589356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19932437A NO313241B1 (no) 1991-01-24 1993-07-05 Fusjonsproteiner med blandet spesifisitet

Country Status (18)

Country Link
US (1) US5709859A (no)
EP (1) EP0568645B1 (no)
JP (1) JP3394534B2 (no)
KR (1) KR100259061B1 (no)
AT (1) ATE195254T1 (no)
AU (1) AU648398B2 (no)
CA (1) CA2099779C (no)
DE (1) DE69231333T2 (no)
DK (1) DK0568645T3 (no)
ES (1) ES2148173T3 (no)
FI (1) FI109203B (no)
GR (1) GR3034524T3 (no)
IE (1) IE920202A1 (no)
IL (1) IL100731A (no)
NO (1) NO313241B1 (no)
NZ (1) NZ241357A (no)
WO (1) WO1992012994A1 (no)
ZA (1) ZA92467B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
EP0689599B1 (en) * 1993-01-25 1998-12-09 Dana-Farber Cancer Institute, Inc. Chimeric selectins by exchange of domains - uses thereof
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6228590B1 (en) 1998-03-23 2001-05-08 Genentech, Inc. Method of selection for genes encoding secreted and transmembrane proteins
ATE329622T1 (de) * 1998-04-15 2006-07-15 Lexigen Pharm Corp Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
WO2000058501A2 (en) * 1999-03-26 2000-10-05 The Wistar Institute Novel genetic suppressor elements and methods of making the same
KR20020018197A (ko) * 1999-05-19 2002-03-07 추후보정 Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
JP2003534291A (ja) * 2000-05-19 2003-11-18 ザ センター フォー ブラッド リサーチ インク Ｐ−セレクチン活性の変調による止血障害の診断及び治療方法
JP5390055B2 (ja) * 2000-06-29 2014-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
HUP0303428A2 (hu) * 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
AU2002356496A1 (en) * 2001-05-16 2003-04-01 Ceptyr, Inc. Dsp-18 dual-specificity phosphatase
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
PT1699822E (pt) * 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
BRPI0417916A (pt) * 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
MXPA06012987A (es) * 2004-05-11 2007-06-12 Abgenomics Corp Epitopos inductores de muerte de celulas t.
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
RU2437893C2 (ru) * 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
EP2295080A3 (en) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
SG175233A1 (en) * 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
KR101632312B1 (ko) * 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
US8895700B2 (en) 2010-02-18 2014-11-25 Janssen Biotech, Inc. Monkey homolog of human interferon omega
EP2558482B1 (en) 2010-04-16 2017-09-27 Janssen Biotech, Inc. Engineered plant cysteine proteases and their uses
EP2621950A4 (en) 2010-09-27 2015-09-02 Janssen Biotech Inc ANTIBODIES FOR BINDING HUMAN COLLAGEN II
JP6296536B2 (ja) 2010-11-05 2018-03-20 メドベット サイエンス ピーティーワイエルティーディーＭｅｄｖｅｔ Ｓｃｉｅｎｃｅ Ｐｔｙ Ｌｔｄ 内皮前駆細胞のマーカーおよびその使用
US20130209449A9 (en) 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
BR112018007538A2 (pt) * 2015-10-15 2018-10-23 Celularity Inc células exterminadoras naturais e células ilc3 e usos das mesmas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DE68929477T2 (de) * 1988-09-28 2004-06-03 Dana-Farber Cancer Institute, Boston Interzellulare Adhäsions-Moleküle und deren Bindungsliganden
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
DE69021456T2 (de) * 1989-05-23 1996-02-15 Otsuka Pharma Co Ltd Monoklonale Antikörper gegen aktivierte endotheliale Zellen.
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules

Also Published As

Publication number Publication date
AU1339192A (en) 1992-08-27
ZA92467B (en) 1992-09-30
NO313241B1 (no) 2002-09-02
EP0568645A4 (en) 1994-09-28
IE920202A1 (en) 1992-07-29
KR930703008A (ko) 1993-11-29
AU648398B2 (en) 1994-04-21
NZ241357A (en) 1994-04-27
US5709859A (en) 1998-01-20
FI933292L (fi) 1993-07-21
KR100259061B1 (ko) 2000-07-01
NO932437L (no) 1993-09-17
JPH06505388A (ja) 1994-06-23
DE69231333T2 (de) 2001-01-18
WO1992012994A1 (en) 1992-08-06
ATE195254T1 (de) 2000-08-15
GR3034524T3 (en) 2000-12-29
IL100731A (en) 1997-07-13
FI109203B (fi) 2002-06-14
IL100731A0 (en) 1992-09-06
DK0568645T3 (da) 2000-09-18
CA2099779C (en) 2002-03-19
EP0568645B1 (en) 2000-08-09
DE69231333D1 (de) 2000-09-14
CA2099779A1 (en) 1992-07-25
JP3394534B2 (ja) 2003-04-07
FI933292A0 (fi) 1993-07-21
ES2148173T3 (es) 2000-10-16
EP0568645A1 (en) 1993-11-10

Similar Documents

Publication Publication Date Title
NO932437L (no) Fusjonsproteiner med blandet spesifitet
Hajjar The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen.
EP0673255A4 (en) MONOCLONAL ANTIBODY, WHICH SPECIFICALLY BINDS TO VASCULARIZED TUMOR DOTHELIUM AND USES THEREOF.
DK0554344T3 (da) Farmaceutisk præparat til behandling eller forebyggelse af en malign tumor
DK0439095T4 (da) Terapeutiske antistofbaserede fusionsproteiner
BR9707379A (pt) Anticorpo humano isolado ácido nucleico isolado vetor recombinante de expressão célula hospedeira processo para sintetizar um anticorpo humano que se liga á TNF Alfa humano composição farmacéutica processo para inibir á atividade do TNF humano e uso do anticorpo
DE10075010I1 (de) Fusionsproteine mit immunglobulinanteilen ihre Herstellung und Verwendung
ATE177475T1 (de) Monoklonale antikörper gegen c-kit
KR950701390A (ko) 비타민 B12/ 트랜스코발라민 II 수용체에 대한 항-수용체 제제(Anti-receptor agents to the vitamin B12/ transcobalamin II receptor)
Paul et al. Human platelet basic protein associated with antiheparin and mitogenic activities: purification and partial characterization.
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
NO172596C (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer, anvendelse av disse og diagnostiske systemer inneholdende disse
Kürschner et al. Construction, purification, and characterization of new interferon gamma (IFN gamma) inhibitor proteins. Three IFN gamma receptor-immunoglobulin hybrid molecules.
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
Kurkela et al. Preparation of F (ab′) 2 fragments from monoclonal mouse IgG1 suitable for use in radioimaging
Neumaier et al. Delineation of four carcinoembryonic antigen (CEA) related antigens in normal plasma by transblot studies using monoclonal anti-CEA antibodies with different epitope specificities
Murkofsky et al. Effect of a disulfide-interchange enzyme on the assembly of human secretory immunoglobulin A from immunoglobulin A and free secretory component.
Suzuki et al. IL-2 receptor subunit, p75: direct demonstration of its IL-2 binding ability by using a novel monoclonal antibody
Ocklind et al. Different cell surface glycoproteins are involved in cell—cell and cell—collagen adhesion of rat hepatocytes
ATE190353T1 (de) Icams konstante domäne wasserlöslichen fusionsproteine, immunoglobulin
Jacques et al. Biochemical study of a recombinant soluble interleukin-2 receptor. Evidence for a homodimeric structure
Hannestad et al. Multiple M-components in a single individual-iI studies on urinary Fab μ like fragments in macroglobulinema
Sorg Use of a radioactive double labeling technique in the chemical analysis of the mediators of cellular immunity
Stein et al. Myeloma producing nonsecretory IgM and secretory IgG
Ditzel et al. Preparation of antigen-binding monomeric and half-monomeric fragments from human monoclonal IgM antibodies against colorectal cancer-associated antigens

Legal Events

Date Code Title Description
MK1K Patent expired